Adaptive Phage Therapeutics gets FDA green light to advance superbug therapy, as COVID-19 ‘underscores the critical need’ - Washington Business Journal

Adaptive Phage Therapeutics can take its therapy for superbugs to human trials.

Image: Dr. Carl Merril, third from right, with his son Greg, CEO and co-founder of Adaptive Phage Therapeutics, and other members of the team. ADAPTIVE PHAGE THERAPEUTICS INC.